Hot Sliver Companies To Buy Right Now

Google's (NASDAQ: GOOG  ) Android, which powers Samsung's flagship devices, has undoubtedly been a disruptive force in the smartphone and tablet market. Even free and open operating systems, however, have not been enough to dethrone Apple (NASDAQ: AAPL  ) from its grasp on the lion's share of profits in the smartphone and tablet market's Apple pioneered in the second Steve Jobs' era.

But what if Google was able to take this same low-cost and open approach for software and apply it to hardware? And what if this approach drove prices of formidable smartphones down to levels we never imagined? How would Apple hold up then?

Project Ara. Image source: Motorola official blog.

A potentially disruptive moonshot
When Google announced on Jan. 29 that it was selling Motorola to Lenovo, Google didn't give up its smartphone hardware efforts entirely. The online search giant decided to keep Motorola's boldest and wildest project. The effort is called Project Ara. What is Project Ara? An undertaking to pioneer an open and modular smartphone with a target price of $50. According to Time, Google hopes to launch Project Ara's $50 smartphone in about a year.

Top Transportation Companies For 2015: NewLink Genetics Corp (NLNK)

NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.

The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.

HyperAcute Cancer Immunotherapy Product Candidates

In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.

HyperAcute Cancer Immunotherapy Technology

The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.

IDO Pathway Inhibitor Product Candidate

The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.

Advisors' Opinion:

• [By Ben Rooney]

  NewLink Genetics (NLNK) is working with the World Health Organization and other agencies on an Ebola vaccine. Its shares have surged 57% in the past month.

• [By Jayson Derrick]

  NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and ��athering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.��Shares fell 16.20 percent, closing at $31.60.

Hot Sliver Companies To Buy Right Now: Humana Inc.(HUM)

Humana Inc. offers various health and supplemental benefit plans in the United States. Its Government segment consists of beneficiaries of government benefit programs; and operates in three lines of businesses, including Medicare, Military, and Medicaid. The Medicare program provides hospital and medical insurance benefits to persons of age 65 and over and some disabled persons under the age of 65. The Military program offers health insurance coverage to the dependents of duty military personnel, and to retired military personnel and their dependents. The Medicaid program is a federal program that is state-operated to facilitate the delivery of health care services primarily to low-income residents. The Commercial segment consists of members enrolled in its medical and specialty products marketed to employer groups and individuals. This segment provides health maintenance organization products that offer prepaid health insurance coverage to its members through a network of independent primary care physicians, specialty physicians, and other health care providers; preferred provider organization products, which are offered primarily to employer groups and individuals; and administrative services only products that are provided to employers who self-insure their employee health plans. It also offers various specialty products, including dental, vision, and other supplemental products, as well as disease management services. As of December 31, 2010, Humana Inc. had approximately 10.2 million members enrolled in medical benefit plans; and approximately 7.1 million members enrolled in specialty products programs. The company markets its products through various channels comprising television, radio, the Internet, telemarketing, and direct mailings. In addition, it has strategic alliances with Wal-Mart Stores, Inc.; State Farm; and United Services Automobile Association to market its products. The company was founded in 1961 and is headquartered in Louisville, Kentucky.

Advisors' Opinion:

• [By Charles Sizemore]

  I��l start with insurance stocks. Given that Americans will now be required to buy health insurance, the industry as a whole should expect to see 48 million new customers (i.e. the number of Americans currently without health insurance). This should be a major boon to insurers like UnitedHealth (UNH), Humana (HUM) and Aetna (AET), right?

• [By DailyFinance Staff]

  Concerns about the political uncertainty in Ukraine caused some volatility in the markets Friday afternoon, with the major indexes making several U-turns ahead of the weekend. The Dow Jones industrial average (^DJI), which had been up by as much as 125 points, briefly dropped into loss territory before rebounding to end 49 points higher. The Standard & Poor's 500 index (^GPSC) edged up 5 points, adding to Thursday's record high, but the Nasdaq composite (^IXIC) lost 10 points. AP/Darko VojinovicPro-Russian militias have seized local government buildings in Crimea, Ukraine; the unrest there is making investors around the world nervous. February was a great month for investors. All three major averages jumped by about 4 percent. UnitedHealth Group (UNH) led the blue chips, gaining 1½ percent. Other health providers – Aetna (AET), Wellpoint (WLP), Cigna (CI) and Humana (HUM) -- all gained between 1½ and 2 percent. And retail stocks remained active. Target (TGT) added another 3 percent. Best Buy rose 4 percent, and Fred's (FRED), a regional department store chain, jumped 10 percent. But Pier 1 (PIR) fell 5½ percent after lowering its earnings outlook for a second time. That led to a series of brokerage downgrades. Decker Outdoor (DECK) tumbled 12 percent. The maker of footwear brands such as Ugg and Teva issued a weak outlook. And apparel maker Lululemon (LULU) fell 5-percent on negative comments from Credit Suisse. It seems as though there are always some big movers in the drug and biotech sectors – and that was certainly the case today. GW Pharmaceuticals (GWPH) rose 2 percent after the FDA granted orphan status to its drug to treat a rare form of childhood epilepsy. But most of the action was on the downside. Endologix (ELGX) slid 24 percent after forecasting lower revenue growth. Questcor (QCOR) fell 10 percent. It's lost big for three straight days amid allegations of questionable business practices. Jazz Pharma

Hot Sliver Companies To Buy Right Now: Ishares Trust S & P Global * (IXJ)

iShares S&P Global Healthcare Sector Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Standard & Poor�� Global Healthcare Sector Index (the Index). The Index is a subset of the Standard & Poor�� Global 1200 Index, and measures the performance of companies that Standard & Poor�� deems to be a part of the healthcare sector. Component companies include healthcare providers, biotechnology companies, and manufacturers of medical supplies, advanced medical devices and pharmaceuticals.

The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By MONEYMORNING.COM]

  Consider the iShares S&P Global Healthcare Sect. (ETF) (NYSE: IXJ). While not a pure European play, it has one of the highest non-U.S. exposures in healthcare, most of which is European, and trades at a more reasonable P/E of 19. The fund is up 8.44% year to date and recently set a new all-time high, so it's definitely got momentum on its side.

Hot Sliver Companies To Buy Right Now: API Technologies Corp (ATNY)

API Technologies Corp. (API), incorporated on February 2, 1999, designs, develops and manufactures systems, subsystems, radio frequency (RF) and secure communications products, as well as provides electronics manufacturing and engineering services. Its product lines include engineered products (including unmanned aerial vehicles (UAVs), aiming systems and synthesizers), secure communications products (including TEMPEST and emanation security, encryption and secure networking products), subsystems and components (including custom hybrids, terminals, transistors and magnetics), RF and microwave products (including custom filters, amplifiers, connectors and antennas), sensors, and power systems. It operates in two segments: Systems & Subsystems, and Secure Systems & Information Assurance. In June 2013, API sold its Data Bus product line to Data Device Corporation.

The Company offers engineering services (including engineering and design for payloads, ground control systems and commercial product design) and electronics manufacturing services (EMS), such as new product introductions (NPI) and prototypes, turnkey manufacturing and printed circuit board (PCB) assembly. It operates in North America, the United Kingdom, Mexico and China.

Systems & Subsystems

The Systems & Subsystems segment includes the products and services of its operating subsidiaries Spectrum, API Defense Inc., API Defense USA Inc., API Systems Inc., SenDEC, National Hybrid Group, API Electronics, Inc., TM Systems, Keytronics, Filtran Limited and Microwave Technology, Inc. (CMT). Its products and services include RF /microwave solutions, Engineered Systems and Products, Subsystems and Hybrids, Electronics Manufacturing Services, Power Solutions, Sensors and Measurement and Engineering Services. It specializes in the development of custom Integrated Microwave Assemblies (IMAs). It develops and markets engineered systems and products, used for force protection, communication, surveillance and reconnai! ssance. Featured solutions include Unmanned Aerial Vehicles (UAVs) and systems, Unmanned Ground Vehicle (UGV) systems, aiming systems and synthesizers.

The Company�� Custom designed and off-the-shelf subsystems from API support mission critical applications, such as communication equipment, aircraft subsystems systems, computer peripherals, process control equipment, and instrumentation. Featured products include custom hybrids, terminals, transistors and magnetics solutions. It deliver Electronics Manufacturing Services (EMS), including: New Product Introductions (NPI) and prototypes, turnkey manufacturing, Printed Circuit Board (PCB) assembly, electro-mechanical assembly, systems integration, test engineering, turnkey box build and supply chain services. Its power products offer commercial and defense customer�� superior power and energy efficiency. Products span power systems management, distribution, and panels, and custom-designed power supplies for defense and aerospace applications.

The Company offers a range of precision sensors and control products, including position sensing solutions for precision guided munitions, gyros, accelerometers, and inertial measurement sensors for defense and aerospace applications, and position and temperature sensors for industrial and commercial applications. It offers a range of design and engineering services for both defense and commercial customers. Featured areas of expertise include payloads, ground control systems, RF, microwave and millimeterwave.

Secure Systems & Information Assurance

The Secure Systems & Information Assurance segment includes the products and services of its subsidiaries Cryptek, Emcon Emanation Control Inc., Secure Systems and Technologies and the Ion Networks division. API offers customers various secure network and hardware solutions, including Emanation Security, Tempest and secures network access, ruggedized systems and secure networking products. Its products are marketed u! nder the ! Cryptek, ION, Emcon, SST and Netgard brand names. These product offerings are sold to governments and other international organizations that require the level of security in the areas of identity validation, network access management, TEMPEST network intrusion prevention, and secure and encrypted fax, computers and telephones.

The Company�� products and services include Emanation Security and TEMPEST Products, Secure Networking Products, Encryption and Professional Services. The Company�� emanation security products include computing systems, network and communications systems and office systems. Its security appliances and software intelligently enables secure information sharing and systems management across organizations and technologies. Service providers, IT and communications equipment manufacturers, enterprises and government agencies rely on its secure networking products for secure systems for remote management, database guards for secure information sharing and secure virtual enclaves.

The Company�� encryption products and services enable Federal, State and Local governments, Department of Defense agencies, the Department of Homeland Security and the Armed Services to interoperate securely across organizational boundaries and untrusted systems. Its professional services include information assurance and secure networking architecture and design solutions, emanation security testing and engineering and security certification and validation.

The Company competes with Aeroflex, Incorporated, Anaren Inc., Data Devices Inc., Kratos Defense & Security Solutions, Inc., DRS.Finmeccanica, Ducommun Incorporated, Cobham plc, Comtech EF Data Corp. and M/A-COM Technology Solutions Inc.

Advisors' Opinion:

• [By Laura Brodbeck]

  Thursday

  Earnings Expected From: Lindsay Corporation (NYSE: LNN), Emmis Communications Corporation (NASDAQ: EMMS), API Technologies Corp. (NASDAQ: ATNY) Economic Releases Expected: Australian unemployment rate, Japanese consumer confidence, French industrial output, Italian industrial output, Bank of England interest rate decision, US initial and continuing jobless claims

  Friday